Quantitative muscle magnetic resonance imaging as a biomarker for inclusion body myositis in clinical trials: exploring the in vivo effects of arimoclomol
Authors' conclusion
Arimoclomol had no significant effects on the qMRI measurements evaluated, consistent with clinical outcomes from the main trial. The qMRI measurements demonstrated both validity and responsiveness, further supporting their potential utility as biomarkers in IBM.
Study context
- Population
- Subset of inclusion body myositis (IBM) participants from a multicentre, randomised, double-blind, placebo-controlled trial; thigh quantitative magnetic resonance imaging (qMRI) at baseline, 12 and 20 months
- Participants
- 18 participants
- Comparison
- Arimoclomol vs placebo
- Arimoclomoln = 8
- Placebon = 10reference
- Primary endpoint
- Treatment effects on thigh qMRI measures (FF, RMA, MTR, T2m, FFa)
Methodological detailsqMRI substudy, multicentre, double-blind, placebo-controlled, mixed model repeated measures (MMRM)
- qMRI substudy
- Multicentre
- Double-blind
- Placebo-controlled
- MMRM
Primary result
As reported in the abstract
qMRI measures, treatment effect
- No significant treatment effects on the qMRI measures were detected
Further findings
Responsiveness to disease progression of fat fraction (FF), remaining muscle area (RMA) and fat fraction apparent (FFa) · 20 months
- Strong responsiveness (standardised response means>0.8, p<0.05)
- >0.8
Construct validity of baseline FF, RMA, magnetisation transfer ratio (MTR) and FFa (thigh and quadriceps)
- Strong construct validity
Longitudinal changes in thigh T2m vs clinical changes
- Strongly correlated with changes in myometry and modified timed up and go velocity
Original publication
Quantitative muscle magnetic resonance imaging as a biomarker for inclusion body myositis in clinical trials: exploring the in vivo effects of arimoclomol. Clin Exp Rheumatol. Published 26 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →